



PATENT

Case Docket No. TOYAM77.001AUS
Date: April 5, 2002


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Toshio Imai, et al.
Appl. No. : 09/963,316
Filed : September 25, 2001
For : USES OF ANTI-CX3CR1
ANTIBODY, ANTI-
FRACTALKINE ANTIBODY
AND FRACTALKINE
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to: United States Patent and Trademark Office, P.O. Box
2327, Arlington, VA 22202, on

April 5, 2002

(Date)


Katsuhiro Arai, Reg. No. 43,315

TRANSMITTAL LETTER


United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Katsuhiro Arai
Registration No. 43,315
Agent of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshio Imai, et al.) Group Art Unit Unknown
App. No. : 09/963,316)
Filed : September 25, 2001)
For : USES OF ANTI-CX3CR1)
ANTIBODY, ANTI-)
FRACTALKINE ANTIBODY)
AND FRACTALKINE)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 5, 2002

By: 

Katsuhiro Arai
Registration No. 43,315
Agent of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TOYAM77.001AUS	APPLICATION NO. 09/963,316
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Toshio Imai, et al.	
		FILING DATE September 25, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	2001-218581	08/14/01	Japan (Concise explanation of the relevance)			abstract	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2.	Toshio Imai, et al., Identification and Molecular Characterization of Fractalkine Receptor CX ₃ CR ₁ , which Mediates Both Leukocyte Migration and Adhesion, Cell, Vol. 91, 521-530, November 14, 1997
	3.	Lili Feng, et al., Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX ₃ CR ₁ <i>Rapid Communication</i>
	4.	Proceedings of the Japanese Society for Immunology, Vol. 30, 2000, p.192; 2-F-270-P/O with an English translation

H:\DOCS\KOA\KOA-2383.DOC
040502

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	